Edgewise Therapeutics (EWTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.01 (+0.03%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $30.26
  • Market Cap

    $2.87 Billion
  • Total Outstanding Shares

    94.69 Million Shares
  • Total Employees

    108
  • Dividend

    No dividend
  • IPO Date

    March 26, 2021
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.edgewisetx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$299.35 Million
Net Cash Flow From Investing Activities$-178.59 Million
Net Cash Flow$11.85 Million
Net Cash Flow From Operating Activities$-108.90 Million
Net Cash Flow From Financing Activities, Continuing$299.35 Million
Net Cash Flow From Operating Activities, Continuing$-108.90 Million
Net Cash Flow, Continuing$11.85 Million
Net Cash Flow From Investing Activities, Continuing$-178.59 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Expenses$147.15 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss$-124.29 Million
Diluted Earnings Per Share$-1.50
Basic Earnings Per Share$-1.50
Other Operating Expenses$28.87 Million
Basic Average Shares$91.99 Million
Diluted Average Shares$91.99 Million
Preferred Stock Dividends And Other Adjustments$0.00
Revenues$0.00
Income/Loss From Continuing Operations Before Tax$-124.29 Million
Research and Development$118.28 Million
Operating Income/Loss$-147.15 Million
Income/Loss From Continuing Operations After Tax$-124.29 Million
Net Income/Loss Attributable To Parent$-124.29 Million
Net Income/Loss Available To Common Stockholders, Basic$-124.29 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Accounts Payable$5.65 Million
Assets$511.28 Million
Liabilities And Equity$511.28 Million
Noncurrent Liabilities$3.45 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$488.88 Million
Equity$488.88 Million
Noncurrent Assets$11.85 Million
Current Liabilities$18.96 Million
Other Current Liabilities$7.12 Million
Wages$6.18 Million
Liabilities$22.41 Million
Other Non-current Assets$1.88 Million
Fixed Assets$9.97 Million
Current Assets$499.44 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.